Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MRC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MRC2 ECD-Fc Recombinant Protein HEK293 expressed for native glycosylation, high purity (>95%), endotoxin controlled. Sequence Verified. Ideal for binding and internalization assays. |
View MRC2 Products |
| Gene Delivery | MRC2 Promise-ORF / Lentivirus Full-length ORF lentiviral particles for stable cell line construction to evaluate functional collagen internalization. |
View MRC2 Products |
| Benchmark Ab | Anti-MRC2 Recombinant Antibody Recombinant positive control antibody derived from clinical benchmark sequences for validation. |
View MRC2 Products |
| Validator | MRC2 siRNA Set Target-specific siRNA pool for knockdown verification in target-validation assays. |
View MRC2 Products |
| Related Target A | MRC1 (CD206) Homologous C-type lectin receptor. Essential for counter-screening to ensure drug specificity and avoid macrophage-mediated off-target toxicity. |
View MRC1 Products |
| Related Target B | TGFB1 (TGF-beta 1) Primary driver of myofibroblast differentiation and MRC2 upregulation in fibrotic diseases. Key pathway partner. |
View TGFB1 Products |
| Related Target C | COL1A1 (Collagen Type I Alpha 1) The primary physiological ligand of MRC2. Crucial for ligand-blocking and competitive inhibition assays. |
View COL1A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation | Human, Mouse, and Cynomolgus MRC2 recombinant proteins available with >95% purity to facilitate preclinical safety profiling. |
| Subfamily counter-screening (MRC1/CD206) | Highly purified recombinant MRC1 proteins available, verified by mass spectrometry, to rule out off-target binding. |
| Lack of clinical-grade positive controls | Sequence-verified clinical benchmark biosimilar antibodies included in the portfolio. |
| False positives in binding assays | Sequence-verified siRNA knockdown sets included for rigorous cellular specificity validation. |
Live MRC2/CD280 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MRC2 (Endo180/UPARAP) therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to Antibody-Drug Conjugates (ADCs) and therapeutic targeting of the tumor microenvironment. Because MRC2 is rapidly internalized via clathrin-coated pits upon ligand binding, it represents an optimal vehicle for intracellular payload delivery in sarcoma, glioblastoma, and aggressive epithelial cancers. As first-generation therapies reach preclinical and early clinical milestones, the next wave of R&D is targeting highly specific epitopes that do not cross-react with other mannose receptor family members, preventing systemic clearance and off-target toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Biotech & Academic Consortia | Sarcoma, Glioblastoma, TNBC | Internalization Assay (Requires HEK293-expressed, native-glycosylated MRC2 ECD-Fc) |
| Monoclonal Antibodies (mAbs) | Oncology-focused Biopharma | Solid Tumors, Fibrotic Diseases | Ligand-blocking assays (Requires native-conformation MRC2 and COL1A1 proteins) |
| Small Molecule Inhibitors | Fibrosis Specialists | Pulmonary Fibrosis, Hepatic Fibrosis | Selectivity assays against MRC1/CD206 (Requires comparative protein panel) |